Malaria, Falciparum: all 390 studies
Page 2 of 4. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.
- Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 YearsCompletedNCT07670377Phase 1
- Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro StudyCompletedNCT07527182Not applicable
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western KenyaCompletedNCT07362498
- Clinical Prediction Models for Pediatric In-Hospital Death Risk in Congolese Severe Malaria Children Using Machine Learning Based-AlgorithmsCompletedNCT07355426
- MDA and Targeted Control Against Plasmodium Carriage in the SahelActive, not recruitingNCT07281443Not applicable
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum MalariaCompletedNCT07235020Phase 2
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-MActive, not recruitingNCT07183371Phase 2
- Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum MalariaCompletedNCT07122232
- Dose Finding Trial of R21/Matrix-M in School ChildrenActive, not recruitingNCT07074665Phase 2
- Clinical Practices for Treating Severe Malaria Caused by P. FalciparumCompletedNCT07027722
- Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum MalariaCompletedNCT06992297Not applicable
- Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in MozambiqueCompletedNCT06970600Not applicable
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)Active, not recruitingNCT06958198Phase 1
- Private Medicine Retailer-based Trial of Malaria Tests and Conditional Treatment Subsidies Among Patients With FeverCompletedNCT06928207Phase 4
- Infant Malaria Vaccine Schedule OptimizationActive, not recruitingNCT06879327Phase 2
- IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe FloodingActive, not recruitingNCT06870344Not applicable
- First-in-Human PfSPZ-LARC2 Vaccination/CHMICompletedNCT06735209Phase 1
- Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina FasoCompletedNCT06652737Phase 1
- Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina FasoCompletedNCT06618885Phase 1
- Performance of an Ultrasensible Malaria Rapid Diagnostic Test Among Pregnant Women in Burkina FasoCompletedNCT06572644
- Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy ParticipantsCompletedNCT06558643Phase 1
- Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantActive, not recruitingNCT06549257Phase 1/2
- Malaria Molecular Surveillance in Mozambique (Phase 2)Active, not recruitingNCT06529237
- Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African ChildrenActive, not recruitingNCT06524336
- Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in MaliCompletedNCT06413108Phase 1/2
- Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African PopulationCompletedNCT06408857Phase 1
- The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination TherapyCompletedNCT06347471Phase 4
- A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™CompletedNCT06320535Phase 1
- Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in LiberiaCompletedNCT06300970Phase 4
- A Study to Investigate the Safety of GSK4024484 in Healthy Adult ParticipantsCompletedNCT06171113Phase 1
- A Study to Compare Two Dosing Regimens for a New Malaria VaccineActive, not recruitingNCT06141057Phase 1
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, MalawiCompletedNCT06083688Phase 4
- Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the CongoCompletedNCT06076213Phase 4
- Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West PapuaCompletedNCT06036030Phase 2
- Comparing Chemoprevention Drugs for School-based Malaria ControlCompletedNCT05980156Phase 4
- A Study to Assess the Safety and Effectiveness of Two Experimental Malaria VaccinesCompletedNCT05978037Phase 1/2
- TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018CompletedNCT05958810
- TES of Artemether-lumefantrine for Pf in the Philippines in 2015CompletedNCT05958693
- Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC)CompletedNCT05878366Not applicable
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum MalariaCompletedNCT05842954Phase 3
- Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba RegencyCompletedNCT05829187Phase 2
- A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.CompletedNCT05790889Phase 1/2
- MSP3-CRM-Vac4All/ Alhydrogel® VaccineStatus unknownNCT05776017Phase 1/2
- Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical TrialCompletedNCT05764746Phase 2/3
- Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity DiagnosticsActive, not recruitingNCT05757167Phase 4
- Association of Diabetes and Metabolic Syndrome With Severe Malaria in CameroonStatus unknownNCT05685875
- Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant PairsActive, not recruitingNCT05676645
- CHILD (Child Health and Infection With Low Density) MalariaCompletedNCT05567016Not applicable
- Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in MaliCompletedNCT05550909Phase 2
- Coadministration of GA2 Sporozoites With AdjuvantsStatus unknownNCT05468606Early Phase 1
- A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK AdultsActive, not recruitingNCT05385471Early Phase 1
- A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21CompletedNCT05357560Phase 1
- Plasmodium Falciparum Genomic Intelligence in MozambiqueCompletedNCT05306067
- Comparing Chemoprevention Approaches for School-based Malaria ControlCompletedNCT05244954Phase 4
- MSP3-CRM-Vac4All/ Alhydrogel® Malaria VaccineStatus unknownNCT05197751Phase 1
- Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-LumefantrineCompletedNCT05192265Phase 2/3
- Vectron T500 (Broflanilide 50WP) for IRS in Tanzania TanzaniaStatus unknownNCT05150808Phase 3
- Evaluation of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Tanzania.Status unknownNCT05125133Not applicable
- Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in MaliCompletedNCT05081089Phase 2
- Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel SitesCompletedNCT05070520Phase 4
- Therapeutic Efficacy Study of AL and DP in Western KenyaCompletedNCT05060198Not applicable
- Plasmodium Vivax Among Duffy Negative Population in Cameroon.Status unknownNCT05058885
- Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in ThailandCompletedNCT05052502Not applicable
- Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria ChemopreventionCompletedNCT04969185
- Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)CompletedNCT04877626Phase 4
- Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination ActivitiesCompletedNCT04864444Not applicable
- Malawi International Center of Excellence in Malaria Research School-based CohortCompletedNCT04858087
- Adjunctive Ivermectin Mass Drug Administration for Malaria ControlStatus unknownNCT04844905Phase 3
- Proactive Community Case Management for Malaria in ZambiaCompletedNCT04839900Not applicable
- Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in CameroonStatus unknownNCT04829695Phase 4
- Attractive Targeted Sugar Bait Phase III Trial in ZambiaActive, not recruitingNCT04800055Not applicable
- Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)CompletedNCT04609098Phase 2
- Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.CompletedNCT04577066Phase 1/2
- Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in YaoundeCompletedNCT04565184Phase 4
- Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in ChildrenCompletedNCT04473768
- Biological Mechanisms in Afebrile P. Falciparum MalariaCompletedNCT04422015
- Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic RepublicWithdrawnNCT04416945Not applicable
- Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in TanzaniaCompletedNCT04318002Phase 1
- A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownNCT04296279Phase 1
- Health Itinerary of Young Children With Suspected Bloodstream Infection in Kisantu General Referral Hospital, DR CongoCompletedNCT04289688
- Nitrite Infusion in Children With MalariaWithdrawnNCT04289558Phase 1
- Controlled Human Malaria Infection Transmission Model - Phase ASuspendedNCT04280692Phase 1/2
- Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.TerminatedNCT04271306Phase 1
- A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownNCT04268420Phase 1
- Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+AmodiaquinStatus unknownNCT04149106Phase 3
- Additional Screening With Sensitives RDTs and MalariaCompletedNCT04147546Phase 3
- VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M VaccineTerminatedNCT04130282Phase 1
- Mass Screening and Treatment for Reduction of Falciparum MalariaCompletedNCT04093765Not applicable
- Short Course Radical Cure of P. Vivax Malaria in NepalCompletedNCT04079621Phase 4
- Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum TransmissionCompletedNCT04049916Phase 2/3
- Diagnostic and Prognostic Biomarkers for Childhood Bacterial PneumoniaCompletedNCT03996967
- A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan AdultsTerminatedNCT03947190Phase 2
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)CompletedNCT03939104Phase 3
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.CompletedNCT03923725Phase 3
- Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic AreasCompletedNCT03916003Phase 4
- Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina FasoCompletedNCT03896724Phase 1/2
- To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve VolunteersCompletedNCT03867331Phase 1
- A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan AfricaCompletedNCT03855995
- Pyramax in Asymptomatic Carriers of P. Falciparum MonoinfectionsStatus unknownNCT03814616Phase 2
- Malaria Vaccine Pilot EvaluationCompletedNCT03806465